GenesisCare - logo
Enquire now
Refer a patient

Your state: AU |

down arrow down arrow

Prostate Cancer

Prostate Cancer
2024-12-02T06:32:48.071Z

ProstACT-Global-203

ProstACT-Global-203
Prostate cancer

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177 Lu) rosopatamab tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously after Androgen Receptor Pathway Inhibitor Treatment

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177 Lu) rosopatamab tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously after Androgen Receptor Pathway Inhibitor Treatment

Trial overview

Clinical Area

Theranostics

Disease / Condition

Prostate cancer

Study Phase

III

Trial Identifiers

NCT06520345 

 

https://clinicaltrials.gov/study/NCT06520345

GenesisCare Location(s)
Principal Investigator(s)
Nuclear Medicine Physician

Dr Aviral Singh

MD PGDipCard MSc FAfNM FRACP - Clinical Head of Theranostics and Nuclear Medicine

Dr Aviral Singh
Aviral
Singh
View Profile
Profile Image - Dr Aviral Singh

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.

You are leaving our website

You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.